WallStSmart

Sanofi ADR (SNY)vsMolson Coors Beverage Company (TAP-A)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 319% more annual revenue ($46.72B vs $11.14B). SNY leads profitability with a 16.7% profit margin vs -19.2%. SNY appears more attractively valued with a PEG of 4.32. SNY earns a higher WallStSmart Score of 49/100 (D+).

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0

TAP-A

Hold

39

out of 100

Grade: F

Growth: 4.7Profit: 4.0Value: 4.0Quality: 4.5
Piotroski: 3/9Altman Z: 0.90
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Intrinsic value data unavailable for TAP-A.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

TAP-A1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Areas to Watch

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

TAP-A4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.752/10

Expensive relative to growth rate

Return on EquityProfitability
-18.2%2/10

ROE of -18.2% — below average capital efficiency

Revenue GrowthGrowth
-2.7%2/10

Revenue declined 2.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bull Case : TAP-A

The strongest argument for TAP-A centers on Price/Book.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Bear Case : TAP-A

The primary concerns for TAP-A are Piotroski F-Score, PEG Ratio, Return on Equity.

Key Dynamics to Monitor

SNY profiles as a mature stock while TAP-A is a turnaround play — different risk/reward profiles.

TAP-A carries more volatility with a beta of 0.45 — expect wider price swings.

SNY is growing revenue faster at 6.9% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

SNY scores higher overall (49/100 vs 39/100), backed by strong 16.7% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Molson Coors Beverage Company

CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA

The Molson Coors Beverage Company, commonly known as Molson Coors, is a multinational drink and brewing company headquartered in Chicago in the United States.

Visit Website →

Want to dig deeper into these stocks?